MedTrace Logo

Xylitol Based Nasal Spray for COVID-19 Treatment

NCT05618483 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2022-11-23

No results posted yet for this study

Summary

Xlear have developed and patented a xylitol containing nasal spray for the treatment of upper-respiratory tract infections. The nasal spray is comprised of xylitol and GSE (Grapefruit Seed extract) which provides antibacterial properties as well as preventing viral adhesion in the nasal passage. Studies into Xlear's antiviral effects on SARS-CoV-2 are currently ongoing but hypothetically, a Xylitol Based Nasal spray may prove to be a useful and inexpensive treatment for COVID-19 infection.

Conditions

  • Respiratory Viral Infection

Interventions

DEVICE

Nasal Spray

The nasal spray is made of xylitol and grapefruit seed extract. The spray is antiviral, but there is no data of its clinical efficacy against Covid-19.

Sponsors & Collaborators

  • Metanoic Health Ltd.

    collaborator INDUSTRY

  • Xlear, Inc

    lead INDUSTRY

Principal Investigators

  • Ahsan W Rathore, MBBS · University of Health Sciences Lahore

  • Saqib Mahmood, MBBS PhD · University of Health Sciences Lahore

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-28
Primary Completion
2023-12-31
Completion
2024-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05618483 on ClinicalTrials.gov